Home›Stock Screener›Concord Biotech

Concord Biotech Share Price Today | Stock Price & Concord Biotech Share Screener

CONCORDBIO Pharmaceuticals & Biotechnology
Live Share Price NSE
₹556.40
▼ -4.60 (-0.82%)
2026-11-19 00:00:00
Live Share Price BSE
₹556.20
▼ -4.85 (-0.86%)
2026-11-19 00:00:00

As of November 19, 2026, the live Concord Biotech share price (NSE: CONCORDBIO) is ₹556.40 on NSE and ₹556.20 on BSE, down 0.82% from the previous close, with shares trading between ₹549.10 and ₹561.00 in today's trading session, and a 52-week range of ₹554.80–₹1,587.50. Track Concord Biotech marketcap in USD to gauge the company's total market size. Use the Concord Biotech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Concord Biotech opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹341 and net income of ₹89, with EBITDA of ₹134, an operating margin of 36.0% and a profit margin of 26.1%.

Concord Biotech Market Cap ₹11,608.21 Cr.
CONCORDBIO P/E Ratio (TTM) 43.40
Concord Biotech P/B Ratio 5.84
EPS (TTM) ₹24.78
Dividend Yield 1.30%
Debt to Equity -
CONCORDBIO 52 Week High ₹1587.50
Concord Biotech 52 Week Low ₹554.80
Operating Margin 36.00%
Profit Margin 26.10%
CONCORDBIO Revenue (TTM) ₹341.00
EBITDA ₹134.00
Net Income ₹89.00
Total Assets ₹2,235.00
Total Equity ₹2,015.00

Concord Biotech Share Price Chart

Track the current stock price of Concord Biotech with an interactive chart. Analyse CONCORDBIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Concord Biotech stock quote in one place.

The quote of ₹556.40 sits between the 52-week low of ₹554.80 and the 52-week high of ₹1,587.50, and the latest session moved -0.82% from the previous close.

Concord Biotech Company Profile - Fundamental Screener

Screen Concord Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CONCORDBIO shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with SUDHIR JAIRAM VAID listed as chairperson or CEO, and it trades under ISIN INE338H01029.

Business Overview

Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO SUDHIR JAIRAM VAID
ISIN INE338H01029

Concord Biotech Balance Sheet Screener

Screen CONCORDBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹2,235, up from ₹2,034 in 2025.

Latest statistics put total assets at ₹2,235 and shareholder funds at ₹2,015.

Item 2026 2025 2024 2023 2022 2021 2020

Assets

Total Assets 2,235 2,034 1,701 1,514 1,313 1,183 941
Current Assets 0 0 0 0 0 0 0
Fixed Assets 789 795 575 593 573 546 240

Liabilities

Total Liabilities 0 0 0 0 0 0 0
Current Liabilities 51 38 32 32 54 77 55
Non-Current Liabilities 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 2,015 1,813 1,527 1,290 1,103 999 770
Share Capital 11 11 11 11 10 10 10
Reserves & Surplus 2,007 1,802 1,516 1,280 1,094 990 761

Concord Biotech Income Statement Screener - Profit & Revenue Analysis

Screen Concord Biotech income statement and profit fundamentals. Analyze CONCORDBIO quarterly results. Concord Biotech reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹341 and net profit was ₹89, equal to earnings per unit of ₹8.46, at an operating margin of 36%.

In that period expenses were ₹208, interest cost ₹0 and tax ₹26. The next period listed, 2026-Jun, shows revenue of ₹272 and net profit of ₹58.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 341 272 319 439 219 263 288 330 228 320 261 285 208 271 252
Expenses 208 175 205 241 143 159 183 187 135 177 146 146 123 147 135

Operating Costs and Margins

EBITDA 134 97 114 198 77 104 105 143 93 144 115 139 85 124 117
Operating Profit % 36.00% 32.00% 34.00% 44.00% 30.00% 36.00% 34.00% 41.00% 38.00% 43.00% 40.00% 47.00% 37.00% 44.00% 44.00%
Depreciation 20 18 18 15 18 18 19 14 13 13 13 14 13 13 14
Interest 0 0 0 0 0 0 0 1 0 0 0 2 1 1 1

Profit and Earnings

Profit Before Tax 114 78 96 184 59 86 86 129 80 130 101 124 71 110 103
Tax 26 21 26 43 15 23 23 34 20 35 25 32 17 29 26
Net Profit 89 58 70 140 44 63 64 95 60 96 76 92 55 81 78
EPS 8.46 5.52 6.65 13.42 4.21 6.03 6.08 9.08 5.70 9.15 7.26 8.75 5.21 7.74 7.41

Concord Biotech Cash Flow Screener - Liquidity Fundamentals

Screen CONCORDBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹267, and net cash flow was an inflow of ₹11.

Over the same period, investing activities used ₹143 and financing activities used ₹113.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March

Cash from Operations and Investing

Operating Activities 267 245 266 246 208 167 155
Investing Activities -143 -160 -155 -158 -112 -195 -114

Financing and Net Cash

Financing Activities -113 -99 -99 -85 -100 31 -43
Net Cash Flow 11 -14 12 3 -5 3 -1

Concord Biotech Shareholding Pattern Screener

See Concord Biotech shareholding pattern with promoter, FII, and DII holdings. Check Concord Biotech promoter holding and ownership changes for CONCORDBIO on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 44.08%, foreign institutions 7.80%, domestic institutions 9.22% and the public 8.09%, spread across 82,249 shareholders.

The shareholder count was 82,249 in 2026-Mar, compared with 83,325 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 44.08% 44.08% 44.09% 44.08% 44.08% 44.08% 44.08% 44.08%

Institutional Investors

FII Holding 7.80% 7.52% 7.28% 9.35% 9.11% 8.03% 7.58% 6.48%
DII Holding 9.22% 9.36% 10.95% 9.16% 8.87% 9.55% 9.58% 8.46%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 8.09% 8.23% 8.81% 6.94% 7.43% 7.77% 8.11% 7.08%
Other Holding 30.81% 30.81% 28.87% 30.47% 30.51% 30.56% 30.64% 33.90%
Shareholder Count 82,249 83,325 88,365 81,219 82,045 82,650 81,815 83,296

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Concord Biotech. Concord Biotech dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹7.55 per unit for 2026-March, a yield of 0.65%, compared with ₹10.70 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹7.55, ₹10.70 and ₹8.75 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹7.55 0.65%
2025-March ₹10.70 1.05%
2024-March ₹8.75 0.52%
2023-March ₹6.83 0.45%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Concord Biotech Stock Index Membership - Nifty & Sensex

See which indices include Concord Biotech stock. Check CONCORDBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 14 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH

Concord Biotech Market Events Screener - Corporate Actions

Get Concord Biotech corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Concord Biotech stock events that may affect CONCORDBIO share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Bonus dated November 4, 2026, with a record date of November 4, 2026.

It is followed by Quarterly Result Announcement dated October 27, 2026 and Quarterly Result Announcement dated July 31, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-04 2026-11-04 Bonus 1:1 -10.92%
2026-10-27 2026-10-27 Quarterly Result Announcement NA 3.42%
2026-07-31 2026-07-31 Quarterly Result Announcement NA 6.11%
2026-07-31 2026-07-31 Annual General Meeting NA 3.83%
2026-07-24 2026-07-24 Dividend ₹ 7.55 /share 15.38%
2026-05-29 2026-05-29 Quarterly Result Announcement NA -4.67%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 9.87%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 4.87%
2025-09-09 2025-09-09 Annual General Meeting NA -2.31%
2025-09-03 2025-09-03 Dividend ₹ 10.70 /share 3.39%
2025-08-08 2025-08-08 Quarterly Result Announcement NA -6.13%
2025-05-29 2025-05-29 Quarterly Result Announcement NA 6.76%
2025-02-13 2025-02-13 Quarterly Result Announcement NA -0.32%
2024-11-11 2024-11-11 Quarterly Result Announcement NA 2.08%
2024-06-29 2024-06-29 Annual General Meeting NA 6.09%

Concord Biotech Competitors Screener - Peer Stocks Comparison

Screen CONCORDBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Concord Biotech Company Announcements - News & Reports Screener

Screen CONCORDBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 12, 2026 and November 12, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-12 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-12 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-12 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-11 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-11 Intimation Of Record Date For Issuance Of Bonus Equity Shares - November 04 2026 -
2026-11-11 Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended On September 30 2026. -
2026-11-11 Board Meeting Outcome for Meeting Held Today I.E. Tuesday October 27 2026 - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) As Amended From Time To Time. -
2026-11-10 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-10-23 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-22 Board Meeting Intimation for Meeting To Be Held On Tuesday October 27 2026 Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-28 Closure of Trading Window -
2026-09-25 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-24 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-09-23 Board Meeting Outcome for The Board Of Director At Its Meeting Held Today I.E. Wednesday September 23 2026 Has Inter-Alia Considered And Approved Issuance Of Bonus Shares & Increase In The Authorised Share Capital Of The Company. -
2026-09-19 Board Meeting Intimation for Meeting To Be Held On Wednesday September 23 2026 Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 Inter-Alia To Consider The Proposal For Declaration Of Bonus Equity Shares To The Existing Equity Shareholders Of -
2026-09-18 Intimation Of Outcome Of U.S. Food And Drug Administration (USFDA) Inspection At Unit II - Valthera Formulation Facility Of The Company -
2026-09-17 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-21 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹556.40, within a 52-week range of ₹554.80 to ₹1,587.50. The P/E ratio is 43.40 and the P/B ratio is 5.84, with earnings per unit of ₹24.78. Market capitalisation stands at ₹11,608.21 Cr and the dividend yield is 1.30%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 18, 2026. This page covers 7 balance sheet periods, 15 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.